Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Clinical trial NCT05690503 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05690503
- Sponsor
- New York State Psychiatric Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-20
- Primary completion
- 2025-06-30
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.